Alto Neuroscience, Inc. (ANRO)

USD 3.64

(-3.96%)

Total Debt Summary of Alto Neuroscience, Inc.

  • Alto Neuroscience, Inc.'s latest annual total debt in 2023 was 151.46 Million USD , up 84.47% from previous year.
  • Alto Neuroscience, Inc.'s latest quarterly total debt in 2024 Q2 was 10.05 Million USD , up 0.45% from previous quarter.
  • Alto Neuroscience, Inc. reported annual total debt of 82.1 Million USD in 2022, up 115.15% from previous year.
  • Alto Neuroscience, Inc. reported annual total debt of 38.16 Million USD in 2021, down 0.0% from previous year.
  • Alto Neuroscience, Inc. reported quarterly total debt of 10.01 Million USD for 2024 Q1, down -93.39% from previous quarter.
  • Alto Neuroscience, Inc. reported quarterly total debt of 151.46 Million USD for 2023 Q4, up 1421.78% from previous quarter.

Annual Total Debt Chart of Alto Neuroscience, Inc. (2023 - 2021)

Historical Annual Total Debt of Alto Neuroscience, Inc. (2023 - 2021)

Year Total Debt Total Debt Growth
2023 151.46 Million USD 84.47%
2022 82.1 Million USD 115.15%
2021 38.16 Million USD 0.0%

Peer Total Debt Comparison of Alto Neuroscience, Inc.

Name Total Debt Total Debt Difference
ADC Therapeutics SA 124.37 Million USD -21.777%
Annovis Bio, Inc. - USD -Infinity%
Biohaven Pharmaceutical Holding Company Ltd. 30.87 Million USD -390.537%
Ginkgo Bioworks Holdings, Inc. 241.76 Million USD 37.352%
Nuvation Bio Inc. 4 Million USD -3679.961%
Nuvation Bio Inc. 4 Million USD -3679.961%
Arcus Biosciences, Inc. 11 Million USD -1276.936%
Theriva Biologics, Inc. 2.15 Million USD -6931.708%
Zymeworks Inc. 26.72 Million USD -466.81%